Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Key Highlights: Implications: The deal adds ~$90–100 million of annualized revenue visibility from 2029, diversifies Gland’s customer base, and strengthens its credibility as a o...
Key Highlights: Implications: The new cGMP/US FDA/EU-compliant suite at Gland’s Visakhapatnam JNPC site, adding ~1,400 kg/year of sterile API capacity, should help both companies capture m...
Key Highlights: Implications: The expansion makes Turbhe more competitive for high-potency peptides, HPAPIs, and biomolecules, helping Piramal attract programs that need safe, sm...
The pharmaceutical industry is entering a new era where innovation is no longer driven by individual organisations alone. From drug discovery and clinical research to manufacturing, regulatory complia...
Key Highlights: Implications: By selling the Roorkee and Noida plants (for around ₹56 crore) but retaining brands, trademarks, its Beauty Entrepreneur network, and all commercial operation...
In recent years, India’s pharmaceutical landscape has witnessed a significant transformation. Beyond being the “pharmacy of the world” for affordable medicines, India is emerging as a preferred global...
Key Highlights: Implications: GTBL’s MicroBiopharm acquisition is a strategic move to become a more integrated, higher-value pharma services and ingredients player. The mai...
Latest Developments in Global Pharma Supply Chains The COVID-19 pandemic exposed critical vulnerabilities in global pharmaceutical supply chains, highlighting the risks associated with overrelia...
Key Highlights: Implications: HRV Pharma is using the Shodhana alliance to turn its AI‑enabled “Virtual API” model into tangible, regulated assets, starting with a pharmaceutical...
